# US 2020/0399349 A1 · Antibody against chikungunya virus or antigen-binding fragment of the antibody, and use of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399349 A1
- Document ID: US20200399349A1
- Status: Published application
- Kind: A1
- Application number: 16/968,470
- Filed: 2019-02-08
- Published: 2020-12-24
- Earliest claimed: 2018-02-09
- Assignees: Osaka University; Mahidol University
- Applicants: Osaka University; Mahidol University
- Inventors: Tatsuo SHIODA; Emi NAKAYAMA; Tadahiro SASAKI; Orapim PUIPROM; Aekkachai TUEKPRAKHON; Pornsawan LEAUNGWUTIWONG; Natthanej LUPLERTLOP
- Web page: https://patentgrep.com/patent/US20200399349A1

## CPC

- C07K 16/116: Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- G01N 33/56983: {Viruses}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/565: Complementarity determining region [CDR]
- C12N 2770/36111: Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- G01N 2333/181: Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a new antibody against ECSA type Chikungunya virus, WA type Chikungunya virus, and Asian type Chikungunya virus or an antigen-binding fragment of the antibody. The antibody against Chikungunya virus or the antigen-binding fragment of the antibody of the present invention includes a heavy chain variable region or a heavy chain (1), (2), or (3) and a light chain variable region or a light chain (4).

## Claims

### Claim 1

An antibody against Chikungunya virus or an antigen-binding fragment of the antibody, comprising the following heavy chain variable region (1), (2), or (3) and the following light chain variable region (4):
(1) a heavy chain variable region comprising heavy chain complementarity determining regions (CDRH)1, CDRH2, and CDRH3:
CDRH1 is a polypeptide comprising the following amino acid sequence (H1-A),
CDRH2 is a polypeptide comprising the following amino acid sequence (H2-A), and
CDRH3 is a polypeptide comprising the following amino acid sequence (H3-A), wherein
(H1-A) the following amino acid sequence (H1-A1), (H1-A2), or (H1-A3):
(H1-A1) an amino acid sequence of SEQ ID NO: 1 (GYTFTSYW),
(H1-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 1, and
(H1-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 1,
(H2-A) the following amino acid sequence (H2-A1), (H2-A2), or (H2-A3):
(H2-A1) an amino acid sequence of SEQ ID NO: 2 (IYPGDGDTRYT),
(H2-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 2, and
(H2-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 2,
(H3-A) the following amino acid sequence (H3-A1), (H3-A2), or (H3-A3):
(H3-A1) an amino acid sequence of SEQ ID NO: 3 (SYDPFDY),
(H3-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 3, and
(H3-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 3,
(2) a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3:
CDRH1 is a polypeptide comprising the following amino acid sequence (H1-B),
CDRH2 is a polypeptide comprising the following amino acid sequence (H2-B), and
CDRH3 is a polypeptide comprising the following amino acid sequence (H3-B), wherein
(H1-B) the following amino acid sequence (H1-B1), (H1-B2), or (H1-B3):
(H1-B1) an amino acid sequence of SEQ ID NO: 4 (GYAFSTSW),
(H1-B2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 4, and
(H1-B3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 4,
(H2-B) the following amino acid sequence (H2-B1), (H2-B2), or (H2-B3):
(H2-B1) an amino acid sequence of SEQ ID NO: 5 (IYPGDGDT),
(H2-B2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 5, and
(H2-B3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 5,
(H3-B) the following amino acid sequence (H3-B1), (H3-B2), or (H3-B3):
(H3-B1) an amino acid sequence of SEQ ID NO: 6 (SNDGYYVGY),
(H3-B2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 6, and
(H3-B3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 6,
(3) a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3:
CDRH1 is a polypeptide comprising the following amino acid sequence (H1-C),
CDRH2 is a polypeptide comprising the following amino acid sequence (H2-C),
CDRH3 is a polypeptide comprising the following amino acid sequence (H3-C), wherein
(H1-C) the following amino acid sequence (H1-C1), (H1-C2), or (H1-C3):
(H1-C1) an amino acid sequence of SEQ ID NO: 7 (GYTFTSYY),
(H1-C2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 7, and
(H1-C3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 7,
(H2-C) the following amino acid sequence (H2-C1), (H2-C2), or (H2-C3):
(H2-C1) an amino acid sequence of SEQ ID NO: 8 (INPSNGGT),
(H2-C2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 8, and
(H2-C3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 8,
(H3-C) the following amino acid sequence (H3-C1), (H3-C2), or (H3-C3):
(H3-C1) an amino acid sequence of SEQ ID NO: 9 (GYYGNPFFAY),
(H3-C2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 9, and
(H3-C3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 9,
(4) a light chain variable region comprising light chain complementarity determining regions (CDRL)1, CDRL2, and CDRL3:
CDRL1 is a polypeptide comprising the following amino acid sequence (L1-A),
CDRL2 is a polypeptide comprising the following amino acid sequence (L2-A),
CDRL3 is a polypeptide comprising the following amino acid sequence (L3-A), wherein
(L1-A) the following amino acid sequence (L1-A1), (L1-A2), or (L1-A3):
(L1-A1) an amino acid sequence of SEQ ID NO: 10 (ENVVTY),
(L1-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 10, and
(L1-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 10,
(L2-A) the following amino acid sequence (L2-A1), (L2-A2), or (L2-A3):
(L2-A1) an amino acid sequence of SEQ ID NO: 11 (GAS),
(L2-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 11, and
(L2-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 11,
(L3-A) the following amino acid sequence (L3-A1), (L3-A2), or (L3-A3):
(L3-A1) an amino acid sequence of SEQ ID NO: 12 (GQGYSYPYT),
(L3-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 12, and
(L3-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 12.

### Claim 2

An antibody against Chikungunya virus or an antigen-binding fragment of the antibody, comprising the following heavy chain variable region (1), (2), or (3) and the following light chain variable region (4):
(1) a heavy chain variable region comprising a polypeptide consisting of the following amino acid sequence (H-A):
(H-A) the following amino acid sequence (H-A1), (H-A2), or (H-A3):
(H-A1) an amino acid sequence of SEQ ID NO: 13,
(H-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 13, and
(H-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 13,
(2) a heavy chain variable region comprising a polypeptide consisting of the following amino acid sequence (H-B):
(H-B) the following amino acid sequence (H-B1), (H-B2), or (H-B3):
(H-B1) an amino acid sequence of SEQ ID NO: 14,
(H-B2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 14, and
(H-B3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 14,
(3) a heavy chain variable region comprising a polypeptide consisting of the following amino acid sequence (H-C):
(H-C) the following amino acid sequence (H-C1), (H-C2), or (H-C3):
(H-C1) an amino acid sequence of SEQ ID NO: 15,
(H-C2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 15, and
(H-C3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 15,
(4) a light chain variable region comprising a polypeptide consisting of the following amino acid sequence (L-A):
(L-A) the following amino acid sequence (L-A1), (L-A2), or (L-A3):
(L-A1) an amino acid sequence of SEQ ID NO: 16,
(L-A2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 16, and
(L-A3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 16.

### Claim 3

An antibody against Chikungunya virus or an antigen-binding fragment of the antibody, comprising the following heavy chain (1), (2), or (3) and the following light chain (4):
(1) a heavy chain comprising a polypeptide consisting of the following amino acid sequence (HA):
(HA) the following amino acid sequence (HA1), (HA2), or (HA3):
(HA1) an amino acid sequence of SEQ ID NO: 17,
(HA2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 17, and
(HA3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 17,
(2) a heavy chain comprising a polypeptide consisting of the following amino acid sequence (HB):
(HB) the following amino acid sequence (HB1), (HB2), or (HB3):
(HB1) an amino acid sequence of SEQ ID NO: 18,
(HB2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 18, and
(HB3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 18,
(3) a heavy chain comprising a polypeptide consisting of the following amino acid sequence (HC):
(HC) the following amino acid sequence (HC1), (HC2), or (HC3):
(HC1) an amino acid sequence of SEQ ID NO: 19,
(HC2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 19, and
(HC3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 19,
(4) a light chain comprising a polypeptide consisting of the following amino acid sequence (LA):
(LA) the following amino acid sequence (LA1), (LA2), or (LA3):
(LA1) an amino acid sequence of SEQ ID NO: 20,
(LA2) an amino acid sequence having 80% or more identity with respect to the amino acid sequence of SEQ ID NO: 20, and
(LA3) an amino acid sequence in which one or several amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 20.

### Claim 4 (depends on 1)

The antibody against Chikungunya virus or the antigen-binding fragment of the antibody according to claim 1, wherein the Chikungunya virus is an envelope glycoprotein of Chikungunya virus.

### Claim 5 (depends on 1)

A detection kit for Chikungunya virus, comprising:
the antibody or the antigen-binding fragment of the antibody according to claim 1.

### Claim 6 (depends on 1, 5)

The detection kit according to claim 5, comprising:
a detection reagent that detects binding between Chikungunya virus and the antibody or the antigen-binding fragment of the antibody. (Currently Amended) A method for detecting Chikungunya virus, comprising:
a detection step of bringing a sample into contact with the antibody or the antigen-binding fragment of the antibody according to claim 1 to bind Chikungunya virus in the sample to the antibody or the antigen-binding fragment of the antibody, thereby detecting Chikungunya virus in the sample.

### Claim 8 (depends on 7)

The method according to claim 7, wherein
the detection step comprises:
a contact step of bringing the sample into contact with the antibody or the antigen-binding fragment of the antibody to bind Chikungunya virus in the sample to the antibody or the antigen-binding fragment of the antibody; and
a binding detection step of detecting binding between the Chikungunya virus and the antibody or the antigen-binding fragment of the antibody.

### Claim 9 (depends on 7)

The detection method according to claim 7, wherein
the sample is body fluid or urine.